Bioniche Receives Regulatory Approval for Equine Supplement

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, announced Oct. 27 that it has received a notice of compliance from Health Canada's Veterinary Drugs Directorate for a low molecular weight hyaluronate sodium product for horses. The company expects to launch in the next several months.

The product, NexHA TM , is a formulation of purified hyaluronate sodium that can be administered to horses by intravenous or intra-articular (IA) injection. It is indicated in the treatment of joint dysfunction of the carpus (knee) or fetlock in horses due to non-infectious synovitis (inflammation of the synovial membranes) associated with equine osteoarthritis. Hyaluronate sodium acts as a replacement for synovial fluid, the naturally occurring lubricant in articular joints. Joint degeneration is associated with the loss of synovial fluid, and the lack of its lubricant effects results in considerable pain and inflammation for the horse.

The company has been selling different formulations of sodium hyaluronate in Canada (IA only), Australia and New Zealand as the product Enhance since 2001/02. Both Enhance and NexHA TM are produced with a sodium hyaluronate solution that is obtained from a selective fermentation source using a manufacturing process that is free from thermal degrading effects.

"Enhance has been a very successful product for us in Australia, and we look forward to making this new formulation--NexHA TM--available to our Canadian equine veterinary customers, followed by veterinarians in other global jurisdictions in the future," said Andrew Grant, president of Bioniche Animal Health.

Stay on top of the most recent Horse Health news with FREE weekly newsletters from Learn More